Compare Indoco Remedies with NALWA SONS INV - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs NALWA SONS INV - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

NALWA SONS INV 
   Change

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES NALWA SONS INV INDOCO REMEDIES/
NALWA SONS INV
 
P/E (TTM) x 136.5 16.4 833.2% View Chart
P/BV x 2.3 1.3 176.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 INDOCO REMEDIES   NALWA SONS INV
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
NALWA SONS INV
Mar-18
INDOCO REMEDIES/
NALWA SONS INV
5-Yr Chart
Click to enlarge
High Rs3171,511 21.0%   
Low Rs178820 21.7%   
Sales per share (Unadj.) Rs113.170.4 160.6%  
Earnings per share (Unadj.) Rs4.516.5 27.1%  
Cash flow per share (Unadj.) Rs11.816.5 71.6%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs73.2720.0 10.2%  
Shares outstanding (eoy) m92.155.14 1,792.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.216.6 13.2%   
Avg P/E ratio x55.570.6 78.5%  
P/CF ratio (eoy) x21.070.6 29.7%  
Price / Book Value ratio x3.41.6 209.0%  
Dividend payout %22.40-   
Avg Mkt Cap Rs m22,8305,991 381.1%   
No. of employees `0005.5NA 136,375.0%   
Total wages/salary Rs m2,2099 25,989.4%   
Avg. sales/employee Rs Th1,910.190,450.0 2.1%   
Avg. wages/employee Rs Th405.02,125.0 19.1%   
Avg. net profit/employee Rs Th75.521,200.0 0.4%   
INCOME DATA
Net Sales Rs m10,419362 2,879.9%  
Other income Rs m471 4,263.6%   
Total revenues Rs m10,466363 2,884.1%   
Gross profit Rs m1,349104 1,293.7%  
Depreciation Rs m6770-   
Interest Rs m2350 78,366.7%   
Profit before tax Rs m484105 460.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7220 356.7%   
Profit after tax Rs m41285 485.4%  
Gross profit margin %12.928.8 44.9%  
Effective tax rate %15.019.3 77.4%   
Net profit margin %4.023.4 16.9%  
BALANCE SHEET DATA
Current assets Rs m5,3731,276 421.0%   
Current liabilities Rs m4,157119 3,483.5%   
Net working cap to sales %11.7319.8 3.6%  
Current ratio x1.310.7 12.1%  
Inventory Days Days6820 340.9%  
Debtors Days Days7326 285.2%  
Net fixed assets Rs m6,2440-   
Share capital Rs m18451 358.6%   
"Free" reserves Rs m6,5663,650 179.9%   
Net worth Rs m6,7503,701 182.4%   
Long term debt Rs m1,233327 377.2%   
Total assets Rs m12,3634,427 279.3%  
Interest coverage x3.1351.3 0.9%   
Debt to equity ratio x0.20.1 206.8%  
Sales to assets ratio x0.80.1 1,031.2%   
Return on assets %5.21.9 272.1%  
Return on equity %6.12.3 266.1%  
Return on capital %9.02.6 344.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,1430-   
Net fx Rs m2,6190-   
CASH FLOW
From Operations Rs m1,227224 547.9%  
From Investments Rs m-1,360-129 1,051.1%  
From Financial Activity Rs m-3882 -18,461.9%  
Net Cashflow Rs m-52197 -537.8%  

Share Holding

Indian Promoters % 59.2 55.4 106.9%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 12.5 0.6 2,083.3%  
FIIs % 6.0 4.2 142.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 39.6 56.6%  
Shareholders   12,805 23,884 53.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TVS SRICHAKRA  TATA INVESTMENT  KITEX GARMENTS  INGERSOLL RAND  FINOLEX INDUSTRIES  



Today's Market

Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

NALWA SONS INV Announces Quarterly Results (3QFY19); Net Profit Up 41.5% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, NALWA SONS INV has posted a net profit of Rs 11 m (up 41.5% YoY). Sales on the other hand came in at Rs 17 m (up 20.1% YoY). Read on for a complete analysis of NALWA SONS INV's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 17, 2019 10:19 AM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS